Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Smith & Nephew PLC Director's Dealing 2022

Feb 23, 2022

4588_dirs_2022-02-23_b1d2e5a8-41ee-41f5-bff6-fd41805dfc6f.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 5561C

Smith & Nephew Plc

23 February 2022

SMITH & NEPHEW PLC

23 February 2022

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS CLOSELY ASSOCIATED WITH THEM.

Smith & Nephew plc (the "Company") announces that it has been informed of changes to the share interests of PDMRs in the Company, detailed below, following completion of the related performance periods.

Smith & Nephew Global Share Plan 2010 (Performance Share Awards):

The following relates to individuals included in the below notification:

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Lapse of a Performance Share Award granted on 7 March 2019 under the Smith & Nephew Global Share Plan 2010
Date of Transaction 2022 - 02 - 22
Place of Transaction Lapse took place outside a trading venue
Name of PDMR

(Position)
Number of ordinary shares under award granted on 07/03/2019 (shown at maximum) Number of ordinary shares lapsed under award (shown at maximum) Number of ordinary shares outstanding under award (shown at maximum)
Helen Barraclough

(Group General Counsel)
12,054 12,054 0
Bradley Cannon

(President, Orthopaedics, Sports Medicine & ENT and Americas)
30,784 30,784 0
Phil Cowdy

(Chief Business Development & Corporate Affairs Officer)
22,564 22,564 0
Simon Fraser

(President, Advanced Wound Management & Global Commercial Operations)
27,166 27,166 0
Elga Lohler

(Chief HR Officer)
26,722 26,722 0
Vasant Padmanabhan

(President, Research & Development)
26,382 26,382 0
Susan Swabey

(Company Secretary)
9,784 9,784 0

Notes:

(i)      Following completion of the performance measurement period, these awards lapsed in full on 22 February 2022.

(ii)     Details regarding the performance against targets as set at the grant date will be disclosed within the Annual Report which is to be published on 7 March 2022.

This announcement is made in accordance with the requirements of Article 19 (3) of the Market Abuse Regulation.

Sarah Carne  

Deputy Company Secretary

Smith & Nephew plc

Tel:      +44 (0) 1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFIFETFLIVFIF